<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00177086</url>
  </required_header>
  <id_info>
    <org_study_id>0412M65851</org_study_id>
    <secondary_id>L9839</secondary_id>
    <secondary_id>3579B</secondary_id>
    <nct_id>NCT00177086</nct_id>
  </id_info>
  <brief_title>Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi</brief_title>
  <official_title>Alfuzosin Hydrochloride to Promote Passage of Distal Ureteral Calculi</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manoj, Monga, M.D.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess improvement in the percentage of spontaneous stone passage for distal
      ureteral calculi for alfuzosin compared to placebo, decrease of pain and narcotic/analgesic
      use associated with stone passage, decrease of the time to spontaneous stone passage, shift
      in the size distribution of stones passed towards larger sizes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2005</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Spontaneous stone passage for distal ureteral calculi</measure>
    <time_frame>increased</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease the pain and narcotic use associated with stone passage</measure>
    <time_frame>decrease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease the time to spontaneous passage</measure>
    <time_frame>decrease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift the size distribution of stones passed towards larger sizes</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Kidney Calculi</condition>
  <condition>Ureteral Calculi</condition>
  <condition>Colic</condition>
  <arm_group>
    <arm_group_label>Alfuzosin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Alfuzosin Hydrochloride</intervention_name>
    <description>One tablet every day for 4 weeks</description>
    <arm_group_label>Alfuzosin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age =&gt;18

          -  &lt;8mm ureteral calculus below the pelvic brim identified by non-contrast CT scan and/or
             intravenous pyelogram

        Exclusion Criteria:

          -  Subject with know hypersensitivity to Alfuzosin hydrochloride or any component of
             Alfuzosin hydrochloride tablets

          -  Pregnant/Nursing females

          -  Solitary kidney

          -  Renal insufficiency (Creatinine&gt;1.8)

          -  Urinary infection (fever &gt;101, positive urine culture, many bacteria on urinalysis)

          -  Moderate or severe hepatic insufficiency (Childs-Pugh categories B and C)

          -  Potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since
             Alfuzosin blood levels are increased

          -  Other alpha-blockers

          -  Phosphodiesterase type 5 inhibitors for erectile dysfunction

          -  Any subject for whom the principal investigator feels it would not be in his or her
             best interest to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manoj Monga, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota and VAMC Minneapolis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>March 15, 2013</last_update_submitted>
  <last_update_submitted_qc>March 15, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calculi</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Ureteral Calculi</mesh_term>
    <mesh_term>Ureterolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

